Distinct Interferon and Intracellular Signaling Signatures in Systemic Lupus Erythematosus and Dermatomyositis by...

Area of Science:

• Immunology
• Molecular Biology
• Genomics
• Proteomics

Background:

• Systemic lupus erythematosus (SLE) and dermatomyositis (DM) are autoimmune diseases with complex molecular underpinnings.
• Understanding shared and distinct biologic pathways in SLE and DM is crucial for developing targeted therapies.
• Immunosuppressive therapies are commonly used in both conditions, necessitating a deeper understanding of their effects on molecular pathways.

Purpose of the Study:

• To compare biologic pathway effects in the peripheral blood of patients with SLE and DM receiving immunosuppressive therapies.
• To identify shared and distinct molecular mechanisms underlying SLE and DM using transcriptomic and proteomic data.
• To explore potential therapeutic opportunities based on identified molecular differences.

Main Methods:

• Peripheral blood samples from patients with SLE (n=41) and DM (n=14) were analyzed using transcriptomic and proteomic platforms.
• Gene and protein expression data were compared with matched healthy controls.
• Regulatory effects were integrated across platforms to assess biologic pathways and downstream signaling within and across disease cohorts.

Main Results:

• Overall, 973 gene loci expressions were altered, with 67 genes shared between SLE and DM, including interferon (IFN) markers and apoptosis-related genes.
• Shared pathways included granulocyte adhesion, immune cell migration, acute-phase response, and L1CAM signaling.
• Distinct findings revealed Type I IFN activation in SLE and increased intracellular kinase signaling in DM.

Conclusions:

• A multi-omics approach identified common immune pathways in SLE and DM.
• Distinct molecular mechanisms, including IFN signaling in SLE and kinase signaling in DM, were identified.
• These shared and distinct molecular signatures highlight potential therapeutic targets for SLE and DM.